crashbandicootremasteredpc| Huaxi Biotech (688363.SH): The company is an early domestic company that recognized the importance of pilot testing and took the lead in building a pilot transformation platform for synthetic biology
Gelonghui May 24 δΈ¨ Huaxi Biotech (688363crashbandicootremasteredpc.SH) said on the investor interaction platform that as the earliest deployment of synthetic biology in China,crashbandicootremasteredpcThe company has built a full industrial chain of synthetic biological green manufacturing covering "R & D innovation, pilot test, industrial transformation, and market transformation". It has the full chain capabilities from "gene editing, strain transformation, cell engineering creation, to pilot test and industrial transformation, and then to market transformation." At the same time, the company is also one of the earliest companies in China that recognized the importance of pilot testing and took the lead in building a pilot transformation platform for synthetic biology. In 2023, the company will use six major R & D platforms, including the synthetic biology R & D platform, to launch a total of 9 new bioactive raw materials products: including 3 pharmaceutical/medical device-grade raw materials, 4 personal care raw materials and 2 Food grade raw materials products. At the same time, micro-crosslinked hyaluronic acid powder products HyacrossTL200, cationic HA, enzymatic sialic acid, polyoligonucleotides, GABA fabric finishing agent, Cordyceps militaris fermentation broth, probiotic combination fermentation products, etc. have completed trial production, and salidroside, carnosine, and human milk oligosaccharides have completed pilot trials.
